HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.

Abstract
An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH-I, which compares etoposide (VP-16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide-associated (therapy-induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued.
AuthorsS Ladisch, H Gadner, M Aricò, V Broadbent, N Grois, A Jacobson, D Komp, H S Nicholson
JournalMedical and pediatric oncology (Med Pediatr Oncol) Vol. 23 Issue 2 Pg. 107-10 ( 1994) ISSN: 0098-1532 [Print] United States
PMID8202031 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Vinblastine
  • Etoposide
  • Methylprednisolone
Topics
  • Drug Administration Schedule
  • Etoposide (administration & dosage, adverse effects, therapeutic use)
  • Histiocytosis, Langerhans-Cell (drug therapy)
  • Humans
  • Leukemia (chemically induced)
  • Methylprednisolone (administration & dosage)
  • Vinblastine (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: